

****Published March 2014****

MarketVIEW: Rabies vaccines (CAT: VAMV055)

Product Name	:	MarketVIEW: Rabies vaccines
Description	:	Global vaccine commercial opportunity assessment
Contents	:	Executive presentation + 1 forecast model
Therapeutic Area	:	Novel vaccines
Publication date	:	March 2014
Catalogue No	:	VAMV055

Background

Rabies is a viral zoonosis caused by all members of the *Lyssavirus* genus and mostly spread by canine vectors. The disease, if untreated is 100% fatal, although almost 100% preventable through timely postexposure prophylaxis (PEP). Rabies causes tens of thousands of deaths each year, mainly in rural areas of Africa and Asia.

Novartis Vaccines and Sanofi are the only Western producers vaccines for rabies with Rabavert/Rabipur and Verorab/Imovax products respectively. Several domestic vaccine manufacturers (DVMs) in China, India and Russia produce rabies vaccines which serve domestic demand; some also export rabies vaccine. China is the largest market for rabies vaccines.

This **MarketVIEW** product is a comprehensive commercial opportunity assessment detailing the current and potential market for rabies vaccine(s) using a patient based value/volume forecast for major rabies endemic markets to 2024. The forecast gives revenues and volume shares for Western competitors in both pre-and postexposure markets. The analysis takes into account the use of different PEP regimens (ID/IM), current/future market trends and gives an up-to-date review of competitor dynamics, and disease epidemiology.

Methodology

VacZine Analytics has closely monitored all significant source material pertaining to Rabies virus. Example, secondary source materials used are literature articles, government websites/databases, medical bodies and associations, conference proceedings and previously analyses (where publically available). Previously published research by **VacZine Analytics** in field of endemic/travel vaccines has also been utilised. *****See Bibliography for exact sources.**

PRODUCT CONTENTS:

Published March 2014 (CAT No: VAMV055)

****This product is composed of a model and summary presentation

Contents – Summary presentation (MS PowerPoint based)

Authors Note
Executive summary
Commercial model: key outputs
Rabies vaccines: estimated PEP and PrEP treatments.
Rabies vaccines: estimated global value (\$m, 2013)
Rabies vaccines: global value forecast to 2024.
Rabies vaccines: global forecast per competitor to 2024.
Rabies vaccines: global volume, 2013
Rabies vaccines: global volume forecast to 2024.
Rabies vaccines: forecast PEP and PrEP treatments.
Forecast methodology
Countries modelled in this analysis.
Rabies vaccines pricing
Future market trends
Rabies: background
Rabies: disease burden.
Rabies: disease burden per country/region
Rabies: disease burden per population
Rabies: disease burden - deaths per country/region
Rabies: disease burden - cases per population
Country/region profiles
China.
China: number of deaths 2002 to 2013
India
Other Asian markets.
US and Europe
Human and canine rabies cases, Europe, 2008-2012
LATAM
Africa
Rabies vaccine schedules
Post-exposure prophylaxis (PEP) schedules

Continued.....

Post-exposure prophylaxis (PEP) schedules: ID-RV
Post-exposure prophylaxis (PEP) WHO schedules
Pre-exposure prophylaxis (PrEP) schedules
Rabies vaccines: competitive landscape
Competitive landscape: Novartis/Marburg
Competitive landscape: NTV producers
Competitive landscape: per vaccine type
Competitive landscape: India/Russia DVMS
Competitive landscape: WHO prequalification
Competitive landscape: summary table
Rabies vaccines: overview of vaccine demand
China
China: estimates of total market value/volume
India
India: estimates of total market value/volume
Other Asian markets.
Other Asian markets: number of PEP treatments.
Other Asian markets: Vietnam
Other Asian markets: Thailand
Africa
Africa: South Africa
LATAM
LATAM: Brazil
Europe/US
PEP rate per 100,000 population/endemic countries
Bibliography
Disclaimer
About **VacZine Analytics**

PAGES: 67 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form

Contents – Vaccine demand model(s) (MS Excel-based) – 1 model

Title sheet
CHARTS
Global volume summary
Global value summary
Novartis (value share)
Sanofi (value share)
Novartis (volume share)
Sanofi (volume share)
Other companies (volume share)
Treatments PEP and PrEP
Country groups
EU (no risk)
EU (low risk)
US, Canada,
EU (PrEP)
US, Canada (PrEP)



Continued.....

Eastern Europe.
Brazil
LATAM (other)
China.
India
Indonesia
Bangladesh
Thailand
Philippines
Vietnam
Nepal
Sri Lanka
Cambodia
Myanmar
Central Asia
Africa
South Africa
Source material
Total population
Price summary
% IDRW
Estimated based PEP use
PEP summary
Estimated PEP use (Africa)
Epidemiology
China epidemiology
World Bank
Backpage

WORKSHEETS: ~84

PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- FULL PRODUCT - USD **\$8995.00**/ GBP **£5625.00**[#] (Region license)*
- PRESENTATION OR MODEL ONLY - USD **\$4995.00** (Region license)*

[#] Indicative rate only. Prevailing rate applied to date of transaction.

*A region is North America, Europe or ROW

For orders in the UK, VAT at 20.0% will be added to final invoice total

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com

This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.



VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and the “**spiral logo**” are UK Registered Trademarks, 2009

BIBLIOGRAPHY:

1. WHO Expert Consultation on Rabies. WHO Technical Report Series; 2013;(982):1-139
2. The South-East Asia Region of the World Health Organization. Regional Strategic Framework for Elimination of Human Rabies. 2012. Available at: <http://www.searo.who.int/topics/rabies/en/>. Accessed January 2014.
3. Jemberu WT et al. Incidence of rabies in humans and domestic animals and people's awareness in North Gondar Zone, Ethiopia. PLoS Negl Trop Dis. 2013 May 9;7(5):e2216.
4. 6th Partners for Rabies Prevention meeting Wolfsberg, Switzerland, July 16-18th 2013.
5. Chinese Academy of Agricultural Sciences. Global Scenario of Rabies. Available at: www.rr-asia.oie.int. Accessed: January 2014.
6. Yin W et al. Challenges and needs for China to eliminate rabies. Infect Dis Poverty. 2013 Oct 2;2(1):23.
7. Chinese Academy of Agricultural Sciences. Rabies In China. September 2011. Available at: www.oie.int. Accessed: January 2014.
8. Zhu WY et al. Current status of canine rabies in China. Biomed Environ Sci. 2012 Oct;25(5):602-5.
9. Gongal G, Wright AE. Human rabies in the WHO Southeast Asia region: Forward steps for elimination. Advances in Preventive Medicine 2011;2011: 383870.
10. Baxter JM. One in a million, or one in thousand: What is the morbidity of rabies in India? J Glob Health. 2012 Jun;2(1):10303
11. Report of the Working Group on Disease Burden for the 12th Five Year Plan. Available at: www.planningcommission.nic.in/aboutus/committee/wrkgrp12/health/WG_3_1. Accessed: January 2014.
12. Rabies In Asia (RIA) Foundation Conference. Colombo, Sri Lanka in November, 2011.
13. World Organisation for Animal Health (OIE). Zoonoses in Humans. Available at: <http://www.oie.int>. Accessed: January 2014.
14. Ly S et al. Rabies situation in Cambodia. PLoS Negl Trop Dis. 2009 Sep 8;3(9):e511.
15. Blanton JD et al. Rabies surveillance in the United States during 2011. J Am Vet Med Assoc. 2012 Sep 15;241(6):712-22.
16. WHO Rabies Bulletin Europe. Available at: <http://www.who-rabies-bulletin.org/>. Accessed: January 2014.
17. PAHO. Rabies Cases Have Declined 95 Percent in the Americas Since 1980. 27 September 2012. Available at: <http://www.paho.org>. Accessed: January 2014.
18. WHO. Rabies country profile. Available at: www.who.int/rabies/epidemiology/Rabies_CP_SouthAfrica_09_2013.pdf. Accessed: January 2014
19. Use of a Reduced (4-Dose) Vaccine Schedule for Postexposure Prophylaxis to Prevent Human Rabies. MMWR. March 19 2010/59(RR02);1-9
20. Appraisal On Implementation Of Intradermal Rabies Vaccination [Idrv] In India - The Kerala Experience. www.rabiesinasia.org/keralareport.pdf
21. Mathew T. From guidelines to ground reality: maximizing the benefits of IDRV in the fourth year of its implementation. Indian J Public Health. 2012 Jul-Sep;56(3):187-8
22. Sanofi 20F For the fiscal year ended December 31, 2012.
23. Building Excellent National Enterprise with World Leading Technology. Available at: <http://www.chengda.com.cn/en/about06.asp/>. Accessed: January 2014.
24. Factory appeals for rabies vaccine funds. January 2011. Available at: <http://www.mmtimes.com/index.php/national-news/4349-factory-appeals-for-rabies-vaccine-funds.html>. Accessed: January 2014.
25. New developments in rabies vaccines. 2011. Available at: http://www.oie.int/eng/A_RABIES/presentations_rage/S2-2%20NewDevelopInVaccine_DrTordo.pdf. Accessed: January 2014.
26. Bharat Biotech in Rs 70 crore capacity expansion. Available at: <http://www.sify.com/finance/bharat-biotech-in-rs-70-crore-capacity-expansion-news--news-jk2bE4cgjbh.html>. Accessed: January 2014.
27. Zydus Cadila receives WHO prequalification accreditation for Rabies vaccine news 14 October 2008. Available at: http://www.domain-b.com/companies/companies_z/Zydus/20081014_rabies_vaccine.html. Accessed: January 2014.
28. Pasteur Institute to release first set of anti-rabies vaccine in June. Available at: http://articles.timesofindia.indiatimes.com/2012-01-25/coimbatore/30662609_1_anti-rabies-vaccine-vaccine-lab-dpt-vaccines. Accessed: January 2014.
29. WHO prequalified vaccines. August 2013. Available at: www.who.int/immunization_standards/vaccine_quality/PQ_vaccine_list_en. Accessed: February 2014
30. National Guidelines for Rabies Prophylaxis and Intra-dermal Administration of Cell Culture Rabies Vaccines. Available at: http://www.ncdc.gov.in/Rabies_Guidelines.pdf. Accessed: January 2014.
31. Rabies vaccine industry analysis. September 2010. Available at: www.p5w.net/stock/lzft/hyyj/201009/P020100921515868972044.pdf. Accessed: January 2014.
32. Rabies in the South-East Asia Region. 2009. Available at: www.searo.who.int. Accessed: January 2014.

33. SEARG. 11th SEARG meeting,. Dar es Salaam,Tanzania, February 2013. Available at: <http://www.searg.info/>. Accessed: January 2014.
34. Tiembre I et al. [Discontinuation of postexposure prophylaxis at the anti-rabies Center of Abidjan, Côte d'Ivoire]. *Bull Soc Pathol Exot.* 2013 Oct;106(4):272-7.
35. Normas Técnicas de Profilaxia da Raiva Humana. Série A: Normas e Manuais Técnicos. Brasília-DF. 2011. Availabe at: http://www.saude.rs.gov.br/upload/1350311087_normas_tec_profilaxia_da_raiva_hum%5B1%5D.pdf. Accessed: January 2014.
36. Schneider MC et al.Current status of human rabies transmitted by dogs in Latin America. *Cad Saude Publica.* 2007 Sep;23(9):2049-63.
37. Expert consultation on rabies post-exposure prophylaxis. Stockholm, 15 January 2009. Available at: www.ecdc.europa.eu/en/publications/Publications/0906_MER_Expert.
38. Crucell. Human monoclonal antibody cocktail for post-exposure prophylaxis against rabies. March 2008. Available at: <http://www.crucell.com/>. Accessed: January 2014
39. Frequently Asked Questions about Bats and Rabies for Health Care Providers. Available at: www.health.wyo.gov/Media.aspx?mediald=5375. Accessed: January 2014.
40. Aylan O et al. Report of the first meeting of the middle East and eastern Europe rabies expert bureau, Istanbul, Turkey (June 8-9, 2010). *Adv Prev Med.* 2011;2011:812515.
41. Situation with rabies in Republic of Belarus.12.10.12. Available at: <http://www.epinorth.org>. Accessed: January 2014.
42. On situation with rabies in Russia. : 30.09.10. Available at: <http://www.epinorth.org>. Accessed: January 2014.

TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client's acceptance of the Service according the description proposed by the Company.
3. **Cancellation policy.** The Company's cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. **Cancellation rights:** For finished documents - a Clients cancellation rights will last for **seven working days** counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client's cancellation rights have ended.
5. Invoicing will **100%** after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on line invoices are payable within **thirty days** of the invoice date.
7. All proposals are quoted in **\$USD dollars or £GBP** and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company's employees and agents with the performance of the Company's obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master **TERMS and CONDITIONS** available upon request.

VacZine Analytics

Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926
E-mail: info@vacZine-analytics.com

About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and "the spiral logo" are UK Registered Trademarks, 2009

Follow us on Twitter [@vaczineanalytic](https://twitter.com/vaczineanalytic)

Signup to our newsletter ExpertREACT - <http://www.vacZine-analytics.com/products-expertreact.asp>

Signup to our free vaccine pipeline database - <http://www.vaccinestats.com>